ASCOMYCIN FACTS |
1. This tiny website was prepared by the students of the OpenUniversity, as the partial fulfillment of the requirements of the seminary in applied biotechnology. Should anyone believe his copyrights have been violated, he may apply to and specify the word ABUSE17 in the subject so that his email could penetrate our spam filter. The offending text will be removed. 2. Some parts of this page might seem to be copied from Wikipedia. This is incorrect. The corresponding Wikipedia article was originally written by Dr AbuAmir.
|
ASCOMYCIN FACTS SHEET
What is AscomycinAscomycin, (aka Immunomycin, FR-900520, FK520), is an ethyl analog of FK506 (tacrolimus) exhibiting potent immunosuppressant abilities. It can be used to treat autoimmune diseases and skin diseases, and can help prevent rejection after an organ transplant. Ascomycin acts by binding to immunophilins, especially macrophilin-12. It appears that Ascomycin inhibits the production of Th1 (interferon- and IL-2) and Th2 (IL-4 and IL-10) cytokines. Additionally, ascomycin preferentially inhibits the activation of mast cells, an important cellular component of the atopic response. Ascomycin produces a more selective immunomodulatory effect in that it inhibits the elicitation phase of allergic contact dermatitis but does not impair the primary immune response when administered systemically. Ascomycin is produced by the fermentation of Streptomyces hygroscopicus. Specifications and Physical/chemical infoCAS Registry Number: 104987-12-4 Ascomycin is a macrolide immunosuppressant produced by fermentation of Streptomyces tsukubaensis or Streptomyces hygroscopicus var. ascomyceticus. Physico-Chemical Properties:White or off-white crystalline powder, mp: 159 °C - 164 ºC; soluble in methanol, ethanol, acetone, ethyl acetate, chloroform; insoluble in water. -------------------------------------- The patentThe fermentationAnalytics
References: Isolation, Purification and Structure Determination:M. Okuhara et al., EP 184162 (1986 to Fujisawa); T. Kino et al., J. Antibiot. 40, 1249 (1987); H. Tanaka et al., J. Am. Chem. Soc. 109, 5031 (1987). Synthesis: T. K. Jones et al., J. Am. Chem. Soc. 111, 1157 (1989). T. K. Jones et al., EP 378318 (1990 to Merck & Co.). HPLC analysis: T. Akashi et al., J. Pharm. Biomed. Anal. 14(3):339-46 (1996); T. Nishikawa et al., Pharm. Res. 10(12):1785-9T (1993).
---------------
|
